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Background: The geographic distribution and burden of dengue is increasing globally. This study aims to evaluate
dengue outbreaks and to substantiate the need for strengthened surveillance, reporting and control in Eritrea.
Methods: Data from two cross-sectional dengue epidemic investigations in 2005 and 2010 were analyzed. Samples
were tested for dengue virus-specific IgM and IgG antibodies using capture enzyme-linked immunosorbent assays.
Dengue vectors’ breeding attributes were characterized and epidemic risk indices determined. National routine
surveillance weekly reports from 2005 to the second quarter of 2015 were analyzed for spatiotemporal trends.
Results: Dengue outbreaks increased in Eritrea from 2005 to 2015 with clinical presentation varying markedly
among patients. The house and container indices for Aedes aegypti were 40 and 39.6 % respectively, with
containers having A. aeqypti varying significantly (P < 0.04). Serum from 33.3 % (n = 15) and 88 % (n = 26) of
clinical dengue cases in Aroget sub-Zoba (district) of Gash Barka Zoba (region) contained anti-DENV IgM
antibody in 2005 and 2006, respectively. The national surveillance data from 2005 to 2015 indicate an overall
spatiotemporal increase of dengue fever.
Conclusions: The increase in dengue outbreaks has been confirmed in Eritrea and necessitates strengthening
of surveillance and health worker and laboratory capacity, as well as targeted vector control interventions.
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Dengue fever (DF) is a tropical vector-borne disease
caused by four sero-types of a single positive-stranded
RNA virus (DENV-1, DENV-2, DENV-3 and DENV-4)
of the genus Flavivirus, [1]. The Aedes aegypti mosquito
is the main vector for dengue fever, with Aedes albopic-
tus being a secondary vector [2]. The infection has a
wide range of symptoms ranging from completely
asymptomatic disease through dengue fever and dengue* Correspondence: jball2@ufl.edu
Ubydul Haque and Emmanuel Chanda are both Senior authors
†Equal contributors
2Department of Epidemiology, University of Florida, Gainesville, FL, USA
3Emerging Pathogens Institute, University of Florida, 2055 Mowry Road,
Gainesville, FL 32610, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zehaemorrhagic fever (DHF). Dengue fever is an acute
febrile condition characterized by flu-like symptoms,
and severe headache, retro-orbital pain, arthralgia and
rash that affects infants, young children and adults, but
seldom causes deaths. DHF is a severe and potentially
deadly complication that involves plasma leakage that, in
turn, causes dengue shock syndrome (DSS), fluid accu-
mulation with respiratory distress, severe bleeding and
extensive organ involvement [1, 2]. Mortality ranges
from less than 1 % in dengue fever to about 26 % in
DHF or DSS depending on the adequacy and timing of
clinical care [1, 3].
Globally, 2.5 billion people live in dengue endemic
areas, with an estimated 390 million infections occurring
annually, and 100 million apparent infections [4–6].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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but DHF can be managed by rapidly administering
fluid and plasma, and by monitoring vital signs [7]. Ac-
cordingly, vector control is presently the only method
available for dengue control. Five vaccines are currently
in development and one has completed phase III trials
but no vaccine is approved yet [8]. This underscores the
need to implement sustainable prevention and control
interventions rather than rely on outbreak response and
case management.
In Africa, where surveillance for dengue remains poor,
epidemics have increased dramatically [9]. Major out-
breaks have occurred in West Africa [10, 11], Southern
Africa [9], and in countries along the eastern coast of
the continent [12]. Equally, confirmed dengue fever
outbreaks have been reported in Eritrea with the first
confirmed outbreak in 2005 following the investigation
of a suspected malaria outbreak [13]. There has been
an increase in the magnitude and spread of the disease
with new outbreaks in 2010 and 2015. The objective of
this paper is to present and discuss dengue epidemio-
logical data from Eritrea and findings from outbreak in-
vestigations during this time period within the context
of recommended control strategies.Methods
Ethical considerations
Ethical clearance for this study was sought from the
Eritrean Ministry of Health’s Research Division’s Ethical
Committee. Informed consent was sought from study
participants, and assent was given by guardians for per-
sons under the consenting age.Data collection
The case definition used in this study follows that issued
by the Eritrean Ministry of Health, based on the World
Health Organization from 1997 has been described in
detail elsewhere [14]. At diagnosis, a dengue fever case
is defined if a patient satisfies the following criteria: 1)
Any person with acute febrile illness of 2–7 days duration
with two or more of the following: headache, retro-orbital
pain, myalgia, arthralgia, rash, haemorrhagic manifesta-
tions, leucopenia (probable case); a probable case with
laboratory confirmation of one of the following: (positive
IgM antibody, rise in IgG antibody titres, acute samples
had positive RT-PCR or viral isolation) (confirmed case);
a probable or confirmed case of dengue hemorrhagic
fever (DHF); and all the above criteria, plus evidence of
circulatory failure manifested by rapid and weak pulse,
and narrow pulse pressure (≤20 mm Hg) or hypotension
for age, cold, clammy skin and altered mental status
(DSS). 2) Patient is from the affected areas. 3) Absence of
malarial parasites in blood [15].This study utilized two main approaches for data col-
lection: analysis of two cross-sectional investigations of
dengue outbreaks in 2005 and 2010 involving epidemio-
logical and entomological approaches; the retrospective
review of health management information system (HMIS)
records from 2005 to 2015; and of integrated disease
surveillance and response (IDSR) weekly reports from
2010 thru the second quarter of 2015.
Epidemic investigations
The first outbreak of dengue fever was identified in
Agordet sub-Zoba (district) of Gash Barka Zoba (region)
in 2005 as a result of the investigation of a suspected
malaria outbreak. The second outbreak was reported from
Massawa sub-Zoba and surrounding areas in Semenawi
Keith Bahri (SKB) Zoba in 2010 [16, 17]. Dengue fever
outbreak investigations were conducted following the
reports using clinical methods as well as laboratory
serological confirmation of active human infection via
viral isolation by cell culture or reverse transcriptase
polymerase chain reaction (RT-PCR) from clinical sam-
ples for detection of DENV RNA. The detection of pre-
vious exposure to DENV was done through enzyme-
linked immunosorbent assays (ELISA) to detect a mini-
mum of a four-fold increase of IgG and IgM antibody
titres to DENV.
Clinical presentation
Patients from the in-patient department (IPD) and out-
patient department (OPD) at the time of the investiga-
tion were examined by a clinician and the symptoms
were recorded in registers at Agordat hospital and the
private clinics. The hospital registers were reviewed
retrospectively and analyzed for spatial and temporal
trends. Case-based outbreak investigation forms were
completed for dengue cases at the OPD and those at
IPD in the Zonal Referral Hospital of Massawa and
Ghedem hospital. Only suspected dengue fever cases
that satisfied the inclusion criteria outlined above were
interviewed, examined and had blood drawn for sero-
logical laboratory analysis using ELISA.
Serological/Laboratory confirmation
Blood samples were collected from suspected dengue
cases and processed for serological screening after ruling
out malaria infection through the blood film test or
rapid diagnostic test (15 samples from Agordet and 26
samples from Massawa). Acute and convalescent sera
were transported on cold chain to the National Health
Laboratory in Asmara and couriered to collaborating
institutions in Kenya for further analysis. Panbio Dengue
IgM antibody capture enzyme-linked immunosorbent
assays (MAC-ELISA) were used per manufacturer in-
structions to detect anti-DENV IgM antibodies in
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been previously described [19], and was performed to
detect anti-DENV IgG antibodies (the threshold for
which was set at a 4-fold increase).
Entomological investigation
Standard entomological techniques were harnessed for
surveillance of immature and adult stages of Ae.
aegypti in the highly affected area of Agordet. All
potential mosquito breeding containers in domestic
and peri-domestic areas of dwellings were searched
for larvae and pupae. Breeding sites characteristics,
household and container indices, proportion of con-
tainers positive for Ae. aegypti, and the epidemic risk
indices were determined. Potential indoor and out-
door resting places were also search for adult mosqui-
toes. Adult and larval morphological identifications
were done in Asmara using appropriate taxonomic
keys [20].
The epidemic threshold and magnitude
The weekly IDSR data from 2012 to 2015 are recorded
in an Excel database and epidemic alert thresholds for
the IDSR data from 2012 to 2015 are calculated based
on the methodology proposed for malaria [21]. The
weekly epidemic alert threshold is calculated when cases
exceed the 75th percentile of the previous year’s weekly
cases for each Zoba and National level. National weekly
trend graphs are plotted for the entire time series along
with the epidemic threshold (Fig. 1), and then broken
down by Zoba (Fig. 2a-f ).
Review of IDSR/HMIS reports
The Eritrean Ministry of Health has been operating an
extensive HMIS database in the central registry since
1998; the HMIS also captures IDSR data. Thus,
complete data for dengue is routinely collected at
health facilities and reported thru the IDSR system
[15]. The data were analyzed to describe the occurrenceFig. 1 National Weekly Dengue Cases and Epidemic Threshold 2012–2015.of dengue virus-symptomatic individuals in absolute
numbers and percentage by place (residence, travel,
type of work) and demographic (age, sex, occupation)
characteristics.Results
Epidemiological investigations
Clinical presentation
At Agordet, clinical presentation after fever varied mark-
edly among the 1142 dengue patients; from headache
(70 %), arthralgia and back pain (41 %), bleeding in the
form of epistaxis (2 %) and myalgia, lymphadenopathy
and retro-orbital pain manifested in 20, 18 and 15 % of
the dengue patients, respectively. At Massawa, out of
the suspected 26 dengue fever cases, 11 (42 %) were
from Ghedem Hospital, while the remaining 15 (58 %)
were from Massawa Hospital. All dengue patients
presented typical signs and symptoms of dengue fever:
high fever, headache, fatigue, muscular or joint pain and
anorexia; none had any signs of bleeding or other
hemorrhagic tendencies. 88 % of all dengue patients
were permanent residents of Massawa sub-Zoba (23/26),
while one was from Debub Zoba and two were from
Maakel Zoba. The distribution of the dengue patients by
occupation varied from soldiers 6/26 (23 %), to students
4/26 (15 %) and construction workers 3/26 (12 %).Epidemic threshold
In Agordet, the third quartile threshold for malaria epi-
demic reporting was crossed in week 8 of the year and
triggered the investigation and confirmation of the dengue
outbreak in week 13 of 2005 (Appendix 1). At Massawa in
2009, the peak incidence of suspected dengue cases in the
Zoba was initially seen in the 9th and 12th weeks, which
then slightly declined and peaked in week 15, 16 and 19.
Then the incidence declined gradually until the 28th week
with no cases (Appendix 2). In 2010, the highest numbers
of cases (211) were recorded in Week 9. However, thereHere blue indicate total and red threshold
a b
c d
e f
Fig. 2 Weekly Dengue Cases (red line) and Epidemic Threshold (blue line) 2012–2015 by Zoba. a is Anseba, b is Debub, c is Maekel, d is G/Barka, e is
NRS and f is SRS
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no deaths in the hospital.
Magnitude
Records of 1132 dengue symptomatic cases were traced
during the period of the outbreak at Agordat hospitaland the private clinics. The outbreak started during week
3 of the year and continued up to week 27 (Appendix 3).
All age groups were affected but the attack rate was high-
est from 20 to 40 years and males were more affected than
females. At the Zonal Referral Hospital of Massawa and
Ghedem hospitals, only 19 % of the dengue cases were
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The outbreak started in November 2009 and continued
till March 2010. No deaths were recorded in either out-
break investigation.
Entomological surveys
Ae. aegypti, was identified in Agordet with high epidemic
risk indices according to both the Breteau Index and
house index. The house and container indices were 40
and 39.6 % respectively. Container positivity for Ae.
aegypti varied significantly from cement tanks (85.3 %)
and clay pots (33.3 %) to plastic tanks (10 %) and iron bar-
rels (4 %) (P < 0.035). At Massawa, breeding sites included
seeping water from public tap water, marshy areas, and
broken pipes with uncountable larval densities.
Serological/Laboratory confirmation
Seropositivity to DENV has been demonstrated in two
geographically segregated places in Eritrea. In 2005,
seropositivity to IgM antibodies to dengue viruses was
33.3 % (n = 15) at Agordet sub-Zoba of Gash Barka Zoba.
In 2010, sero-positivity for DENV-1 was 88 % (n = 26) at
Massawa sub-Zoba and surrounding areas in SKB Zoba.
Review of IDSR/HMIS reports
Data from the HMIS indicate large outbreaks of dengue
fever in 2005 and 2009 in SKB Zoba. The total number
of suspected dengue cases reported increased seven-fold
from 328 in 2008 to 2160 cases in 2009. The attack rate
in 2009 was highest in Ghindae and Massawa, 1513 and
978 per 100,000 people respectively. Outbreaks were
reported in Keren and Anseba Zobas in 2014 and in
Mendefera and Debub Zobas in 2015 (Table 1). Age
and sex-specific attack rates show that dengue had theTable 1 Population and dengue fever cases by year and Zobas in E
Dengue fever cases
Year Anseba Debub DKB Ga
2005 214 28 210 19
2006 11 – 72 8
2007 – – 44 –
2008 1 – 70 880
2009 – – 407 378
2010 1101 31 366 341
2011 742 23 1727 540
2012 948 46 953 434
2013 695 38 1008 677
2014 852 54 711 545
2015 (Jan–June) 493 164 232 255
Population
2015
583,434 953,497 83,004 867highest burden on persons aged 20-39, and that chil-
dren under 5 face a substantial burden of disease which
could be linked to child mortality (Table 2).Spread
National IDSR/HMIS data from 2010 to 2015 indicate
an overall increase in spatial and temporal trends of the
disease (Table 1, Figs. 1 and 2a-f ).Discussion
Dengue fever is an epidemic prone disease that is rapidly
expanding globally [22] and in Eritrea, as evidenced by the
results of the present study. This study is the first to de-
scribe the clinical features of suspected, probable and con-
firmed dengue cases, and to confirm dengue epidemics in
Eritrea. The analysis of the IDSR/HMIS data indicates a
rapid spatial and temporal spread of the disease to almost
the entire country (Table 1 and Fig. 3). The most common
Ae. aegypti breeding sites in the study areas were cement
tanks (85.3 %) and clay pots (33.3 %) which need to be tar-
geted for an effective control of immature stages of the
vector. Furthermore, house and container indices indicated
that Ae. aegypti is widespread among cement tanks and
clay pots, indicating that targeting peri-domestic and do-
mestic breeding sites with larvicide and other environmen-
tal management interventions may be effective in reducing
the burden of dengue in Eritrea [23, 24]. Integrated vector
control strategies have been shown to be effective at
reducing the burden of dengue in other endemic countries
such as Thailand (e.g. [25], Vietnam e.g. [26]), Costa Rick,
Egypt and Kenya [27], may also be effective in Eritrea.
Despite the existence of potentially effective interven-
tions, technical capacity for health workers to control
dengue outbreaks remains a notable challenge in Eritrea.ritrea
sh Barka Maekel NRS SRS National
239 – 3771 4481
28 – 269 388
266 3 349 662
5 – 328 1284
11 1 2150 2947
4 298 11 7725 12,946
5 461 51 5786 14,195
3 545 318 5786 12,939
7 424 305 3256 12,503
1 56 184 3581 10,889
5 235 241 2951 6871
,818 671,390 1114 440,241 3,599,384
Table 2 Age and sex-specific attack rates
Age
group
Attack rate/1000
Males Females Total
<5 44.75 34.95 40.00
5–9 17.48 19.19 22.55
10–19 39.42 27.09 33.09
20–29 92.61 41.03 56.51
30–39 86.79 37.99 52.27
40–49 63.70 20.84 37.19
50+ 22.97 13.68 17.99
Total 42.49 27.60 34.30
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IDSR unit 10 weeks after its onset, only after failing to
confirm a malaria outbreak [17]. This late reporting is
not uncommon as dengue diagnostic criteria are non-
specific and approximately 70 % of all infections are
asymptomatic [28]. Thus, the epidemics described here
provide a conservative estimate of the true burden and
distribution of dengue in Eritrea. Though there were no
cases of dengue mortality reported in Eritrea, it isa b
d e
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Fig. 3 The spatial and temporal distribution of Dengue Fever in Eritrea 201probable that dengue in Eritrea may be underreported
for various reasons including low awareness of the dis-
ease among health providers, poor surveillance, possible
misdiagnosis due to overlap with malaria cases and lack
of relevant systems for definitive diagnosis at health
stations [21]. The lack of an in-country laboratory to
confirm dengue serotypes underscores the need to
strengthen public health infrastructure in Eritrea.
Data on the spatial and temporal distribution, abun-
dance and ecology of Ae. aegypti in Eritrea remain
sparse and there has not been a surveillance system that
would map the areas at risk of dengue in Eritrea. While
the numbers of containers with Ae. aegypti larvae and
eggs during this entomological survey for dengue were
low, the house and container indices were higher than
the recommended thresholds of 3 and 4 %, respectively,
indicating a potential epidemic risk [29]. Household and
container epidemic risk indices have been shown to not
be useful for assessing risk of infection as they do not con-
sider factors such as population density, temperature,
human habits and population immunity [30, 31]. Studies
have demonstrated that dengue virus infection rates are
temperature-dependent, demonstrating increased infection
and transmission rates at higher temperatures until ac
f
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creases [32–36]. This could partially explain the observed
spatial spread of dengue across Eritrea, where average tem-
peratures are usually high and have minimal fluctuations.
However, in Eritrea there seems to be an association be-
tween altitude and dengue fever; previous outbreaks were
in Agordat Zoba, 604 m above sea level (masl), Massawa
Zoba, 20 masl, and in Ghindae Zoba, 915 masl. Recent
outbreaks in 2014 in Keren Zoba, which is 1422 masl, and
in 2015 in Mendefera Zoba, which is 1954 masl. may indi-
cate ecological niche expansion and an increased risk of in-
fection for the densely populated highland communities in
Eritrea.
To further explore the association between environ-
mental factors and dengue cases and identify the high
risk areas for dengue transmission in Eritrea, IDSR data
and entomological surveillance data including informa-
tion from cross sectional surveys should be correlated
with environmental data at Zoba, sub-Zoba and commu-
nity levels. This will optimize the use of the limited
resources available for dengue fever prevention and
control, facilitate identification of high-risk areas, and
increase the effectiveness of interventions. Eritrea should
conduct a seroprevalence survey in a random sample of
the population to determine which serotypes are circu-
lating and to identify relevant correlates of infection.
This study demonstrates spatiotemporal spread of
dengue in Eritrea during 2005–2015 indicating that
preventative strategies for dengue fever and other po-
tential disease vectored by Aedes aegypti should be
strengthened to achieve the most cost-effective out-
comes [17, 21]. The data presented here are limited and
subject to reporting biases mentioned above, which are
related to Eritrea’s limited dengue surveillance infra-
structure. As such, our results are descriptive because
statistical analyses would not reliably quantify spread.
Furthermore, cross-reaction of DENV with other arbo-
viruses is a problem that could have influenced our
results—there could be false positive dengue cases
where the patient was in fact infected by another arbo-
virus. Additionally, rapid tests were designed for out-
breaks, and the application of these tests in serosurveys
may change the reliability of the tests.
Expanding preventative measures should be coupled
with extensive entomological surveillance to have a sus-
tained impact on dengue burden.
Conclusion
There is a notable increase in dengue outbreaks in
Eritrea, which necessitates strengthening of surveillance,
health worker and laboratory capacity as well as targeted
interventions including vector control. This would allow
for faster, more efficient outbreak responses, and improved
health outcomes for dengue patients. Increased capacityfor vector control would allow for the development, imple-
mentation, and then monitoring and evaluation of inte-
grated vector control strategies and community education
campaigns to reduce the vector population.Appendix 1Appendix 2Appendix 3
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